专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190237157A1 Quantitation and Modeling of Quality Attributes of Therapeutic Monoclonal Antibodies 审中-公开
公开(公告)号：US20190237157A1
公开(公告)日：2019-08-01
申请号：US16264044
申请日：2019-01-31
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Xiaobin Xu , Yu Huang
IPC分类号： G16B5/20 , G06F17/11
CPC分类号： G16B5/20 , C07K16/00 , C07K2317/00 , G01N33/6842 , G01N33/6854 , G01N2440/00 , G06F17/11 , G16B20/20
摘要： Methods of predicting an in vivo serum concentration of an antibody with a post-translational modification of interest after administration of the antibody are provided, as are methods for predicting a subject's exposure to post-translational variants of the antibody. The methods include predicting a percentage of the antibody with the post-translational modification of interest using an in vivo rate constant determined for the post-translational modification, and multiplying the predicted percentage of the antibody with the post-translational modification of interest by the in vivo concentration of the antibody to determine the concentration of the antibody with the post-translational modification of interest.

2. 发明申请

US20190204337A1 SAPOSIN LIPOPROTEIN PARTICLES AND LIBRARIES FROM CRUDE MEMBRANES 审中-公开
公开(公告)号：US20190204337A1
公开(公告)日：2019-07-04
申请号：US16326545
申请日：2017-08-21
申请人： Salipro Blotech AB
发明人： Dr. Jens Frauenfeld , Robin LÖVING
IPC分类号： G01N33/68 , A61K39/00
CPC分类号： G01N33/6842 , A61K9/127 , A61K9/5068 , A61K9/5089 , A61K38/18 , A61K39/0012 , A61K47/42 , A61K47/46 , G01N2570/00
摘要： The invention is directed to a process for preparing a library of saposin lipoprotein particles, wherein the particles comprise membrane components from a cell or an organelle membrane and a lipid binding polypeptide that is a saposin-like protein belonging to the SAPLIP family of lipid interacting proteins or a derivative form thereof, wherein the process comprises the steps of a) providing a mixture of crude membrane vesicles obtained from a cell or an organelle membrane; b) contacting the mixture of step a) with the lipid binding polypeptide in a liquid environment; and c) allowing for self-assembly of the particles. The invention also provides a process for preparing a purified saposin lipoprotein particle comprising the steps of preparing a library according to the process described above and the additional step of f) purifying the saposin lipoprotein particle from the library. In addition, the invention provides a library of saposin lipoprotein particles and saposin lipoprotein particles obtainable according to the processes of the invention. These can be used in medicine, in particular in preventing, treating or lessening the severity of a disease or for use in a diagnostic method, a cosmetic treatment or for use as vaccination formulation or as a tool for drug development, drug screening, drug discovery, antibody development, development of therapeutic biologies, for membrane or membrane protein purification, for membrane protein expression, for membrane and/or membrane protein research, in particular lipidomics and proteomics, preferably for the isolation, identification and/or study of membranes and/or membrane proteins or creation of a lipidome or proteome database.

3. 发明申请

US20190194709A1 Methods of Combining the Detection of Biomolecules Into a Single Assay Using Fluorescent In Situ Sequencing 审中-公开
公开(公告)号：US20190194709A1
公开(公告)日：2019-06-27
申请号：US16288200
申请日：2019-02-28
申请人： President and Fellows of Harvard College
发明人： George M. Church , Evan R. Daugharthy , Richard C. Terry
IPC分类号： C12P19/34 , C12Q1/6874 , C12Q1/682 , C12Q1/6834 , C12N15/10
CPC分类号： C12P19/34 , C12N15/1093 , C12Q1/682 , C12Q1/6834 , C12Q1/6874 , G01N33/6842 , C12Q2543/10 , C12Q2563/107
摘要： The present disclosure provides methods that combine RNA fluorescent in situ sequencing (FISSEQ) with other molecular detection modalities, forming an integrated panomic detection platform. In various embodiments, the present disclosure provides systems and methods to prepare a biological sample to preserve the spatial relationships of biomolecules of interest within the biological sample for FISSEQ detection.

4. 发明申请

US20180259518A1 METHODS FOR IDENTIFYING PATTERNS OF IFN INDUCED EXPRESSION AND USE IN DIAGNOSIS, MONITORING AND THERAPY 审中-公开
公开(公告)号：US20180259518A1
公开(公告)日：2018-09-13
申请号：US15973688
申请日：2018-05-08
申请人： THE JOHNS HOPKINS UNIVERSITY
发明人： John Clayton Hall , Livia Casciola-Rosen , Antony Rosen
IPC分类号： G01N33/564 , G01N33/68 , C12Q1/6886
CPC分类号： G01N33/564 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , G01N33/6842 , G01N33/6866 , G01N33/6893 , G01N2800/102
摘要： The present inventors identified a subpopulation of genes induced by type I and type II IFNs in a human submandibular gland (HSG) epithelial cell line. Unexpectedly, it was found that the majority of genes that are highly up-regulated by IFN-α are also highly induced by IFN-γ. In contrast, there was a substantial group of genes that are highly induced by IFN-γ only. In target tissues, this identified subpopulation of genes and probes allow different IFN patterns to be discerned, enabling more precise molecular classification of patient subpopulations. The identified gene probes are useful for selecting and monitoring therapy, and for defining efficacy of novel agents in the autoimmune rheumatic diseases.

5. 发明申请

US20180256687A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASE AND USES THEREOF 审中-公开
公开(公告)号：US20180256687A1
公开(公告)日：2018-09-13
申请号：US15547436
申请日：2016-01-28
申请人： LEUVAS THERAPEUTICS
发明人： Carlo LAUDANNA , Lucia DE FRANCESCHI
IPC分类号： A61K38/46 , C12Q1/42 , G01N33/68
CPC分类号： A61K38/465 , C12Q1/42 , C12Y301/03048 , G01N33/6842 , G01N2333/916 , G01N2440/14
摘要： Composition and methods are provided for the specific manipulation of protein tyrosine phosphatase (PTP) activity, including without limitation manipulation of protein tyrosine phosphatase receptor type gamma (PTPRG). The modulation of PTP activity can be performed in vitro or in vivo, and is useful for therapeutic and research purposes. In some embodiments, an effective dose of a PTP modulator is provided to an individual for preventing or treating disease involving dysregulated tyrosine kinase activity and/or signaling mechanisms involving tyrosine phosphorylation and/or tyrosine kinase activity. In other embodiments, a PTP modulator is utilized in the analysis and screening of phosphatase pathways in a cell.

6. 发明授权

US10067143B2 Ubiquitination assay 有权
公开(公告)号：US10067143B2
公开(公告)日：2018-09-04
申请号：US13695271
申请日：2011-04-28
申请人： Jonathan Peter Clark
发明人： Jonathan Peter Clark
IPC分类号： G01N33/68 , C12Q1/37 , G01N33/542
CPC分类号： G01N33/6872 , C12Q1/37 , G01N33/542 , G01N33/6842 , G01N33/6845 , G01N2500/00
摘要： The present application relates to a method of assaying ubiquitination in a sample by combining ubiquitin together with a substrate in a sample containing UBE1, UbcH3, Skp2-isoform 1, Skp1, Cull, Rbx1, Cks1, CDK2 and Cyclin E1 under conditions suitable for ubiquitination to take place, exposing the sample to a labelled binding partner which is specific for the ubiquitin, and measuring the amount of ubiquitin bound to the substrate.

7. 发明申请

US20180217155A1 PROTEOMIC ANALYSIS OF SUBCELLULAR COMPARTMENTS 审中-公开
公开(公告)号：US20180217155A1
公开(公告)日：2018-08-02
申请号：US15745261
申请日：2016-07-13
申请人： UNIVERSITÉ DE BORDEAUX , INSERM - INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
发明人： Frédéric SALTEL , Anne-Aurélie RAYMOND , Zakaria EZZOUKHRY
IPC分类号： G01N33/68 , G01N33/58 , G01N1/28
CPC分类号： G01N33/6842 , G01N1/2813 , G01N33/582 , G01N33/6848 , G01N2001/284 , G01N2458/15 , G01N2570/00
摘要： Some embodiments are directed to a method for the subcellular proteomic analysis of a test biological sample, including metabolic isotopic labelling of proteins of a test biological sample, fixing of the sample, labelling of the test subcellular compartment, laser microdissection of said subcellular compartment, extracting the proteins of said subcellular compartment, reversion of the fixing and proteolysis, analyzing the peptides obtained by mass spectrometry, and identifying the analyzed peptides.

8. 发明授权

US09988609B2 Fructose amino acid oxidase, preparation method and enzyme-containing kit for detecting glycated albumin 有权
公开(公告)号：US09988609B2
公开(公告)日：2018-06-05
申请号：US15108320
申请日：2014-12-11
申请人： NINGBO MEDICAL SYSTEM BIOTECHNOLOGY CO., LTD.
发明人： Bingde Zou , Jihua Zou , Yi Wang , Jianghua Jia
IPC分类号： C12Q1/26 , C12N9/62 , C12N9/06 , G01N33/68
CPC分类号： C12N9/0032 , C12Y105/03 , G01N33/6842 , G01N2333/765 , G01N2333/90638 , G01N2333/90672
摘要： Fructosyl amino acid oxidase is provided, which has an amino acid sequence as shown in SEQID. No. 1 or fructosyl amino acid oxidase having a homology of more than 80% with this amino acid sequence, on a corresponding site of an amino acid selected from following (a) to (f), having one or more amino acid residues conducting a substitution, obtained fructosyl amino acid oxidase having a higher thermostability: (a) 59-site glutamic acid, (b) 98-site glutamic acid, (c) 225-site glycine, (d) 277-site lysine, (e) 285-site glutamic acid, and (f) 355-site aspartic acid. The method for preparing the above oxidase and the test kit containing the enzyme for determining glycated albumin are also provided.

9. 发明申请

US20180095098A1 Method for Selecting Agents that Bind to Transmembrane Receptors in a Conformationally Selective Manner 审中-公开
公开(公告)号：US20180095098A1
公开(公告)日：2018-04-05
申请号：US15844319
申请日：2017-12-15
申请人： The Board of Trustees of the Leland Stanford Junior University
发明人： Aaron Michael Ring , Aashish Manglik , Andrew Kruse , Brian K. Kobilka
IPC分类号： G01N33/74 , C07K14/705 , G01N33/566 , G01N33/68
CPC分类号： G01N33/74 , C07K14/705 , C07K14/70571 , G01N33/566 , G01N33/6842 , G01N2333/726 , G01N2570/00
摘要： Provided herein are several methods for selecting agents that bind to transmembrane receptors in a conformationally-selective way. In some embodiments, the method may comprise producing: a transmembrane receptor in an active conformation; and said transmembrane receptor in an inactive conformation and using cell sorting to select, from a population of cells comprising a library of cell surface-tethered extracellular capture agents, cells that are specifically bound to either the transmembrane receptor in its active conformation or the transmembrane receptor in its inactive conformation, but not both. In other embodiments, the method may comprise: contacting a GPCR with a population of cells that comprise a library of surface-tethered extracellular proteins; labeling the cell population with a conformationally-specific binding agent, e.g., a G-protein or mimetic thereof; and using cell sorting to select from the cell population cells that bind to the agent.

10. 发明授权

US09891229B2 Method for determining ubiquitin chain length 有权
公开(公告)号：US09891229B2
公开(公告)日：2018-02-13
申请号：US15711432
申请日：2017-09-21
申请人： Tokyo Metropolitan Institute of Medical Science
发明人： Yasushi Saeki , Hikaru Tsuchiya , Ai Kaiho , Keiji Tanaka
IPC分类号： G01N33/68 , C07K14/47
CPC分类号： G01N33/6842 , C07K14/4702 , G01N33/6803
摘要： Protein ubiquitylation, an essential post-translational modification, regulates almost every cellular process including protein degradation, protein trafficking, signal transduction, and DNA damage response in eukaryotic cells. The diverse functions of ubiquitylation are thought to be mediated by distinct chain topologies resulting from eight different ubiquitin linkages, chain lengths, and complexities. Currently, ubiquitin linkages are generally thought to be a critical determinant of ubiquitin signaling. However, ubiquitin chain lengths, another key element of ubiquitin signaling, have not been well documented especially in vivo situation during past three decades from the discovery of ubiquitin. The reason of this was simply because no method has been available for determination of ubiquitin chain length in endogenous ubiquitylated substrates. In the present invention, a practical technique for determining the actual length of substrate-attached polyubiquitin chains from biological samples is established. Using the method, the mean length of substrate-attached polyubiquitin chains was determined and the robustness of ubiquitin chain length regulation in cells is investigated. The following is a summary of findings in this invention: 1. A method for determining ubiquitin chain length was developed and this method was named ‘ubiquitin protection from trypsinization’ (Ub-ProT). 2. Using Ub-ProT, it was determined that the mean length of substrate-attached ubiquitin chains is in the dimer to decamer range. 3. By quantitative proteomics, it was found that the mean lengths of five major types of ubiquitin chains can be divided into two groups. 4. Proteasome-inhibition did not alter the mean length of substrate-attached polyubiquitin chains, indicating that cells have a robust system for regulating ubiquitin chain length.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式